Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
21.34
-0.02 (-0.09%)
At close: Dec 5, 2025, 4:00 PM EST
21.52
+0.18 (0.84%)
After-hours: Dec 5, 2025, 7:30 PM EST
Avadel Pharmaceuticals Revenue
Avadel Pharmaceuticals had revenue of $77.47M in the quarter ending September 30, 2025, with 54.86% growth. This brings the company's revenue in the last twelve months to $248.52M, up 79.88% year-over-year. In the year 2024, Avadel Pharmaceuticals had annual revenue of $169.12M with 504.79% growth.
Revenue (ttm)
$248.52M
Revenue Growth
+79.88%
P/S Ratio
8.30
Revenue / Employee
$1,321,899
Employees
188
Market Cap
2.09B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AVDL News
- 17 hours ago - Announcement relating to despatch of Rule 15 proposal - GlobeNewsWire
- 2 days ago - Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting - GlobeNewsWire
- 4 days ago - Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting - GlobeNewsWire
- 17 days ago - Alkermes raises offer for Avadel after Lundbeck bid - Reuters
- 17 days ago - Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc - PRNewsWire
- 19 days ago - Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
- 19 days ago - Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal” - GlobeNewsWire
- 21 days ago - Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal - Benzinga